Pharma THC Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 316 studies associated with Pharma THC.
Here is a small sampling of Pharma THC studies by title:
- Δ9-Tetrahydrocannabinol (THC): A Critical Overview of Recent Clinical Trials and Suggested Guidelines for Future Research
- Cannabis-opioid interaction in the treatment of fibromyalgia pain: an open-label, proof of concept study with randomization between treatment groups: cannabis, oxycodone or cannabis/oxycodone combination-the SPIRAL study
- Inhaled Δ9-tetrahydrocannabinol does not enhance oxycodone-induced respiratory depression: randomised controlled trial in healthy volunteers
- Climbing the Evidence Pyramid: Dosing Considerations for Medical Cannabis in the Management of Chronic Pain
- Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review
Components of the Pharma THC Research Dashboard
- Top medical conditions associated with Pharma THC
- Proven effects in clinical trials for Pharma THC
- Receptors associated with Pharma THC
- Individual study details for Pharma THC
Ready to become a subscriber? Go to our PRICING page.
Page Quick Links
Select New Cannabinoid
Overview - Pharma THC
Description of Pharma THC
Pharmaceutical drugs [i.e., Dronabinol (Marinol®, Syndros®) and also Nabilone (Cesamet®)] containing THC correspond to a cannabis chemotype I. They represent a class of drugs produced and standardized from synthetic sources.
Here we highlight dronabinol:
- Dronabinol is a synthetic version of THC.
- FDA approved in 1985 for the tx of HIV/AIDS-induced anorexia & chemotherapy-induced nausea.
- Off-label use includes chronic pain, obstructive sleep apnea, substance abuse, and withdrawal.
- The standard dose for research is 5mg THC. The National Institute for Drug Abuse (NIDA) declared to measure and report clinical research findings using a standard unit of delta-9-tetrahydrocannabinol (THC) of 5 mg (NIDA, 2021).
- Dronabinol is available as soft gelatin capsules: 2.5 mg (white), 5 mg (dark brown), and 10mg (orange).
- Contraindications to dronabinol include a history of hypersensitivity reaction to sesame oil or THC derivatives.
- The most common adverse effects may include changes in cognition, dizziness, euphoria, nausea, anxiety, vomiting, or abdominal discomfort.
- Dronabinol has a half-life of ~4 hours.
- An estimated lethal human dose of dronabinol (IV) is 30 mg/kg (i.e., 2100 mg/ 70 kg).
- Dronabinol has an onset time of ~ 1/2 to 1 hour with a peak effect at 2 to 4 hours.
- Dronabinol has not been evaluated for geriatric or pediatric use.
While Dronabinol (Marinol®, Syndros®) and Nabilone (Cesamet®) are synthetic forms of delta-9-THC, both have different molecular formulas (see names text box), resulting in diverse adverse effects potential for more information on the differences of potential adverse effects between Dronabinol (Marinol®, Syndros®) and Nabilone (Cesamet®) see below.
In this systematic review and meta-analyses of clinical trials (2022), Dronabinol presented 111 "diverse but not severe" adverse effects, while Nabilone presented 40.
- Occurrences of dizziness and dry mouth were most commonly noted in both Dronabinol and Nabilone treatment groups. Similarly, nausea, drowsiness, and fatigue occurred with similar frequency.
- However, adverse effects of dizziness, dry mouth, and headache were significantly higher in patients treated with Dronabinol.
- Drowsiness was >7 x as frequent in patients treated with nabilone than in the placebo group.
Other Names:
Pharmaceutical THCDronabinol (Marinol®, Syndros®) is a synthetic delta-9-tetrahydrocannabinol, Delta-9-THC (plus various other supplier-based synonyms).
IUPAC Name: (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
Molecular Formula: C21H30O2
Source–PubChem
Nabilone (Cesamet®) is a synthetic delta-9-Tetrahydrocannabinol derivative. (plus various other supplier-based synonyms).
IUPAC Name: (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-9-one
Molecular Formula: C24H36O3
Source–PubChem
Pharma THC Properties and Effects
Only Members can view Properties and Effects information. See DEMO page.
Pharma THC Receptor Binding
Only Members can view Receptor Binding information. See DEMO page.
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
